All Posts By

Smartkarma Daily Briefs

Daily Brief Macro: [ETP 2025/04] WTI Falls on Trump’s Push for Higher Oil Output and more

By | Daily Briefs, Macro

In today’s briefing:

  • [ETP 2025/04] WTI Falls on Trump’s Push for Higher Oil Output, Henry Hub Climbs on Colder Forecasts
  • Regional Economics: Navigating the Minefield of Economic Risks
  • CX Daily: Venture Capital in China Flounders as State Takes Over (Part 2)
  • Japan: 25bp Rate Hike To 0.5% (Consensus 0.5%) in Jan-25
  • Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber
  • HEW: Realising Policy Divergence


[ETP 2025/04] WTI Falls on Trump’s Push for Higher Oil Output, Henry Hub Climbs on Colder Forecasts

By Suhas Reddy

  • For the week ending 17/Jan, U.S. crude inventories fell by 1m barrels, missing expectations of a 2.1m barrel decrease. Gasoline stockpiles rose less than expected.
  • U.S. natural gas inventories fell by 223 Bcf for the week ending 17/Jan, missing analyst expectations of a 270 Bcf drawdown. Inventories are 0.7% above the 5-year seasonal average.
  • J.P. Morgan, HSBC, TD Cowen, Barclays, and Citigroup raised their 12-month PTs on SLB post its Q4 earnings. Halliburton reported a YoY decline in Q4 revenue and EPS.

Regional Economics: Navigating the Minefield of Economic Risks

By Manu Bhaskaran

  • Tighter financial conditions, energy market shocks, and China’s shaky recovery raise the risk that multiple downside factors may converge and amplify each other in 2025.   
  • Emerging Asia’s economic growth and currency stability are at risk as heightened uncertainty hurts export demand, portfolio capital flows and foreign investment.  
  • The region does have the policy space to respond to these risks but this will come at the price of tolerating weaker currencies and slower fiscal consolidation.

CX Daily: Venture Capital in China Flounders as State Takes Over (Part 2)

By Caixin Global

  • Funds / In Depth: Venture Capital in China flounders as state takes over (Part 2)
  • Davos /China will treat foreign and domestic firms equally, Vice Premier tells Davos
  • Insurance /China to pump $13.7 billion of insurance funds into stock markets

Japan: 25bp Rate Hike To 0.5% (Consensus 0.5%) in Jan-25

By Heteronomics AI

  • The BoJ raised its policy rate by 25 basis points to 0.5%, consistent with market expectations and reflecting a gradual recalibration of monetary policy as inflationary pressures stabilise near 2.5–3.0% in the medium term.
  • Persistent wage growth, yen depreciation, and improving labour market conditions underpin inflation forecasts. However, due to commodity price volatility and exchange rate sensitivity, inflation risks are tilted to the upside.
  • While financial conditions remain accommodative, future rate hikes are likely if inflation expectations and wage-price dynamics sustain alignment with the BoJ’s medium-term stability target of 2%.
This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.

Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber

By Vinod Nedumudy

  • Transaction valued at around US$701 million in cash proceeds
  • Goodyear to hold ground in Europe until the end of 2025
  • Goodyear joins Dutch research body TNO for crash mitigation

HEW: Realising Policy Divergence

By Phil Rush

  • The chasm between the US and European PMIs compressed, removing this justification for the massive Fed-ECB policy divergence in the price. Ironically, their policies are set to start diverging next week with the ECB cutting while the Fed holds rates.
  • The BOJ hiked while the Norges Bank approached its first cut in March. Meanwhile, UK pay awkwardly surged, but rising unemployment will help justify a cut on 6 February. Sweden, Canada, Chile, Brazil, and Colombia will also announce policy before then.
  • Note: Smartkarma will become the sole distributor of our research in February, so clients should prepare their access now (send queries to transition@smartkarma.com).

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Singapore: SGX Rubber Future TSR20 and more

By | Daily Briefs, Singapore

In today’s briefing:

  • Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber


Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber

By Vinod Nedumudy

  • Transaction valued at around US$701 million in cash proceeds
  • Goodyear to hold ground in Europe until the end of 2025
  • Goodyear joins Dutch research body TNO for crash mitigation

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Samsung Electronics, Seoul Guarantee Insurance, Samsung Life Insurance and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Converting Samsung Life’s Samsung Electronics Stake to Long-Term Holdings: Clearing up the Confusion
  • Seoul Guarantee IPO: Price Cut, Dividend Focus, But Overhang and Weak Earnings May Hurt
  • Samsung Life Insurance: Implications of Classifying Samsung Electronics as a Long-Term Holding
  • Seoul Guarantee Insurance Corp IPO Preview (Significantly Lower IPO Price Range)


Converting Samsung Life’s Samsung Electronics Stake to Long-Term Holdings: Clearing up the Confusion

By Sanghyun Park

  • Samsung Life needs FSC approval for a 10-year holding plan on its Samsung Electronics stake. Without it, the whole plan could fall apart, so it’s all about regulatory green lights.
  • If FSC approves Samsung Life’s long-term holding, they can’t sell those shares for at least 5 years—no exit strategy for the next half-decade due to regulatory rules.
  • Samsung Life will convert part of its stake into long-term holdings, signaling how future buybacks and special dividends will balance in Samsung Electronics’ next shareholder return program.

Seoul Guarantee IPO: Price Cut, Dividend Focus, But Overhang and Weak Earnings May Hurt

By Sanghyun Park

  • Seoul Guarantee Insurance is sticking to the same playbook, focusing on boosting dividend appeal, with a better price and the 100% secondary sell-down and KDIC stake dump still in place.
  • There’s doubt about market interest, as the performance drop from 2023 to 2024 raises concerns over meeting the 200B KRW minimum dividend promise.
  • Seoul Guarantee is Korea’s only pure-play surety insurer, tied to the domestic economy. The IPO lacks a growth plan to reduce this reliance, which would’ve been a key win.

Samsung Life Insurance: Implications of Classifying Samsung Electronics as a Long-Term Holding

By Douglas Kim

  • Samsung Life Insurance (032830 KS) is considering on a special measure of classifying its stake in Samsung Electronics (005930 KS) as a long-term holding stock of up to 10 years.
  • If Samsung Life Insurance’s stake in Samsung Electronics is classified as a long-term holding, Samsung Life Insurance cannot sell Samsung Electronics stocks for at least 5 years.
  • There is an increasing probability that if Samsung Life Insurance classifies its stake in Samsung Electronics as a long-term holding, the current ownership stake structure involving Samsung Group remains intact.

Seoul Guarantee Insurance Corp IPO Preview (Significantly Lower IPO Price Range)

By Douglas Kim

  • Seoul Guarantee Insurance Corp (SGIC) is trying for another attempt at an IPO at much lower IPO price range. The IPO price range is from 26,000 won to 31,800 won.
  • At the high end of the IPO price range, the IPO offering size is 222 billion won. The IPO price range has been lowered by 34% to 39%. 
  • Despite the company’s consistent record of generating positive operating profit, its lack of sales growth and declining operating margins in 2024 remain key concerns.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief United States: OpenAI, Smithfield Foods, Natural Gas, Exxon Mobil, Beta Bionic, Infinity Natural Resources, Venture Global LNG, Blend Labs , Geo Group, Noodles & Co and more

By | Daily Briefs, United States

In today’s briefing:

  • Stargate. It’s Not All About You Microsoft. Or You Either Elon
  • Smithfield Foods (SFD): IPO Provides a Compelling Discount to Industry Peers
  • [ETP 2025/04] WTI Falls on Trump’s Push for Higher Oil Output, Henry Hub Climbs on Colder Forecasts
  • [Earnings Preview] Exxon Q4 Profitability Faces Pressure from Lower Oil Prices and Refining Margins
  • Beta Bionic, Inc. (BBNX): IPO Is An “Execution Story” And in Growth Mode
  • Infinity Natural Resources (INR): Lean & Unlevered IPO Is Next Intriguing Energy Play
  • Venture Global Inc. (VG): First Large IPO of the Year Falls Flat Following Massive Cut in Price
  • Blend Labs Inc (BLND) – Friday, Oct 25, 2024
  • Geo Group Inc (GEO) – Friday, Oct 25, 2024
  • NOODLES & CO (NDLS) – Thursday, Oct 24, 2024


Stargate. It’s Not All About You Microsoft. Or You Either Elon

By William Keating

  • President Donald Trump announced the Stargate Project, a new company which intends to invest $500 billion over four years building new AI infrastructure for OpenAI in the United States.
  • Elon Musk is miffed, Microsoft says they “approved” the project and have a new Right of First Refusal agreement in place with OpenAI. 
  • Stargate is exclusively for OpenAI and the press release states that its mission is to provide a strategic capability to protect the national security of America and its allies.

Smithfield Foods (SFD): IPO Provides a Compelling Discount to Industry Peers

By IPO Boutique

  • The company is seeking a market cap of $9.1b-$10.7b based on the $23-$27 range. 
  • A high end pricing for Smithfield values the company at roughly 13.5x this year’s earnings, a sizable discount to comps Hormel Foods (about 21x) and Tyson Foods (26x).
  • It is our opinion that the business model is well-rounded, resilient and stable with multiple-organic growth levers.

[ETP 2025/04] WTI Falls on Trump’s Push for Higher Oil Output, Henry Hub Climbs on Colder Forecasts

By Suhas Reddy

  • For the week ending 17/Jan, U.S. crude inventories fell by 1m barrels, missing expectations of a 2.1m barrel decrease. Gasoline stockpiles rose less than expected.
  • U.S. natural gas inventories fell by 223 Bcf for the week ending 17/Jan, missing analyst expectations of a 270 Bcf drawdown. Inventories are 0.7% above the 5-year seasonal average.
  • J.P. Morgan, HSBC, TD Cowen, Barclays, and Citigroup raised their 12-month PTs on SLB post its Q4 earnings. Halliburton reported a YoY decline in Q4 revenue and EPS.

[Earnings Preview] Exxon Q4 Profitability Faces Pressure from Lower Oil Prices and Refining Margins

By Suhas Reddy

  • ExxonMobil’s Q4 revenue is expected to rise 2.5% YoY while its EPS is anticipated to fall 36.3%. Annual revenue and EPS are expected to fall by 1.9% YoY and 18.1%.
  • Exxon expects Q4 2024 upstream earnings to drop USD 500–900 million QoQ due to lower crude prices, with refining margins further reducing earnings by USD 300–700 million.
  • ExxonMobil plans to invest up to USD 30 billion in low-emission projects by 2030, with its Low Carbon Solutions business expected to contribute an additional USD 2 billion in earnings.

Beta Bionic, Inc. (BBNX): IPO Is An “Execution Story” And in Growth Mode

By IPO Boutique

  • The company has jumped from just eight sales territories in Q2 2023 to 43 sales to end 2024 with more than 15,000 units installed.
  • An existing shareholder is on the cover of the prospectus with a concurrent private placement
  • Medical Device IPOs have a strong history of success as many are poised for growth

Infinity Natural Resources (INR): Lean & Unlevered IPO Is Next Intriguing Energy Play

By IPO Boutique

  • With an unlevered balance sheet, Infinity Natural Resources is set to for both organic and M&A growth post-IPO.
  • The company is coming public at a discount to peers Diversified Energy, Gulfport Energy and Magnolia Oil & Gas.
  • Early channel check of this offering revealed that the deal is oversubscribed with a high-quality schedule across different regions. 

Venture Global Inc. (VG): First Large IPO of the Year Falls Flat Following Massive Cut in Price

By IPO Boutique

  • Venture Global priced 70 million shares at $25 and the stock closed 4% below issue in its opening session.
  • The underwriting lineup grossly mispriced the IPO from the start and needed to drastically reduce the price range of the transaction.
  • The impact to the greater IPO market will be felt on the next large transaction.

Blend Labs Inc (BLND) – Friday, Oct 25, 2024

By Value Investors Club

  • BLND’s stock price has decreased, resembling CVNA’s past struggles
  • BLND has been restructuring its cost base and balance sheet to prepare for future growth
  • The company, led by a young CEO, is poised for potential recovery and positive earnings revisions, drawing parallels to CVNA’s path to success

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


Geo Group Inc (GEO) – Friday, Oct 25, 2024

By Value Investors Club

  • The GEO Group is a potential investment opportunity with an asymmetric Trump trade, with a price target of $77 in a 2-year time horizon and a blue sky upside target of $103
  • The company’s market cap is $2.1 billion with an enterprise value of $3.9 billion
  • The thesis is based on the potential increase in funding for ICE monitoring under the next administration, potentially leading to the eventual spin-off of the monitoring business, resulting in GEO’s EBITDA potentially more than doubling from the current $500 million through various growth opportunities

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


NOODLES & CO (NDLS) – Thursday, Oct 24, 2024

By Value Investors Club

  • Noodles & Co is currently undervalued, presenting an opportunity for turnaround
  • Despite past challenges, the restaurant chain is statistically cheap and attracting activist investors
  • With potential catalysts and a focus on value, Noodles & Co may be poised for success in the current economic landscape

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief India: Dr. Reddy’s Laboratories, Bharti Airtel and more

By | Daily Briefs, India

In today’s briefing:

  • Dr. Reddy’s Laboratories (DRRD IN): Q3FY25 Result- Subdued US Business Dents Margin; Somber Outlook
  • Lucror Analytics – Morning Views Asia


Dr. Reddy’s Laboratories (DRRD IN): Q3FY25 Result- Subdued US Business Dents Margin; Somber Outlook

By Tina Banerjee

  • Dr. Reddy’s Laboratories (DRRD IN) reported Q3FY25 US business revenue of INR33.8B, up 1% YoY, mainly dragged by lower contribution from Lenalidomide. Q3FY25 EBITDA margin deteriorated to 27.5% (Q3FY24: 29.3%).
  • Limited growth catalysts remain major overhang. No near-term key launches lined-up to fill the void created by Lenalidomide. Moreover, paltry new launches in the U.S. entail limited revenue visibility.
  • Lack of near-term catalyst and bleak growth outlook justify cheaper valuation of Dr. Reddy’s. We do not consider Dr. Reddy’s as value buying opportunity and remain bearish on the name.

Lucror Analytics – Morning Views Asia

By Trung Nguyen

  • In today’s Morning Views publication we comment on developments of the following high yield issuers: Bharti Airtel, SK Hynix, Adani Green Energy, Wynn Macau, New World Development
  • In the US, initial jobless claims for the week ended January 18th rose slightly to 223 k (220 k e / 217 k p). Meanwhile, continuing claims climbed to a three-year high of 1.90 mn (1.87 mn e / 1.85 mn p).
  • Treasuries ended mixed yesterday. The yield on the 2Y UST declined 1 bp to 4.29%, while the yield on the 10Y UST grew 3 bps to 4.64%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: JD.com Inc (ADR), Goldman Sachs Group and more

By | China, Daily Briefs

In today’s briefing:

  • [JD.com, Inc (JD US, BUY, TP US$52) TP Change]: C4Q24 Preview: Still the Safe Choice into 2025
  • Asia Real Estate Tracker (24-Jan-2025): Goldman Sachs expands into Japan with data centre JV.


[JD.com, Inc (JD US, BUY, TP US$52) TP Change]: C4Q24 Preview: Still the Safe Choice into 2025

By Ying Pan

  • We expect JD.com C4Q24 revenue/non-GAAP NI to be RMB337bn/9.7bn, 1.6%/6.5% above consensus, benefiting from trade-in subsidies and logistics;
  • With 2025 having four quarters of trade-in subsidy vs. 2024’s one quarter and smartphone’s participation, JD.com is on solid growth footing in our universe. 
  • We raised JD.com’s TP from US$50 to US$ 52 TP and maintain BUY rating.

Asia Real Estate Tracker (24-Jan-2025): Goldman Sachs expands into Japan with data centre JV.

By Asia Real Estate Tracker

  • Goldman Sachs’ GCI enters partnership with Asia Pacific Land in Japan for data center venture, expanding its reach in Asia.
  • CPPIB and MGRV collaborate on $350M venture in Korean rental housing, aiming to capture opportunities in the real estate market.
  • S&P forecasts rebound in China’s property market, driven by increase in secondary sales, indicating positive growth.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Tsuruha Holdings, Resona Holdings, SGX Rubber Future TSR20, TSE Tokyo Price Index TOPIX, Astellas Pharma and more

By | Daily Briefs, Japan

In today’s briefing:

  • Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table
  • Japanese Big Cap Banks – Revisiting Interest Rate Sensitivities
  • Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber
  • ETF Sale Won’t Be Concluded Soon, but as Long as BOJ Keeps Holding Them, the Problems Will Persist
  • Astellas Pharma (4503 JP): Xtandi & Forex Lead To Guidance Revision, Impairment Losses One Off Burnt


Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table

By Travis Lundy

  • In late December, a Jiji article said Tsuruha & Welcia would look to integrate by end-2025, now that they no longer need SEC approval. Odd language, but we’ll take it.
  • That means we look to what might happen between here and there. The companies will hire Legal and Financial Advisors, wait until both report FY, then start negotiating.
  • What has been the long-term trend and the trend of the last two years is different. It’s worthwhile looking at valuations and expectations to decide how to trade. It’s good.

Japanese Big Cap Banks – Revisiting Interest Rate Sensitivities

By Victor Galliano

  • BoJ raised rates to 0.5% at its January policy meeting and BoJ Governor Kazuo Ueda hinted at more rate hikes; BoJ’s new Outlook Report forecasts higher core inflation in 2025
  • We reiterate our core recommendations Resona and Mizuho for their leverage to higher interest rates, their low LDRs, their high levels of cash at the BoJ and their modest valuation
  • We also keep our buys on Concordia and Shizuoka, for their leverage to higher interest rates and LDRs below 90%, along with their attractive valuations highlighted by low PEGs

Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber

By Vinod Nedumudy

  • Transaction valued at around US$701 million in cash proceeds
  • Goodyear to hold ground in Europe until the end of 2025
  • Goodyear joins Dutch research body TNO for crash mitigation

ETF Sale Won’t Be Concluded Soon, but as Long as BOJ Keeps Holding Them, the Problems Will Persist

By Aki Matsumoto

  • Since dividend income and unrealized gains on ETFs have significant impact on BOJ’s finances, the sales of ETF will be discussed, considering BOJ’s overall balance sheet and income/expenses as well.
  • There’re unexamined issues, whether the central bank’s purchase of stocks was really good thing, whether it distorted the secondary market, and whether management reforms were delayed by underpinning the stocks.
  • BOJ can move on to the issue of ETF disposition when the impact of policy rate hikes is recognized and the market stabilizes, but until then the problems will persist.

Astellas Pharma (4503 JP): Xtandi & Forex Lead To Guidance Revision, Impairment Losses One Off Burnt

By Tina Banerjee

  • Astellas Pharma (4503 JP) revised FY25 revenue guidance upward to ¥1900B on robust Xtandi performance and favourable forex movement. Core profits and margins will also see upward revisions and expansions.
  • The company will record an impairment charge of ¥176B for intangible assets this fiscal. As a result, FY25 operating profit on reported basis will come down to ¥11B from ¥80B.
  • Recently, Astellas has received approval for Vyloy and label expansion approval for Padcev in China. Label expansion application for Izervay in the U.S. has been accepted by the FDA.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: ZTO Express Cayman , Cameco Corp, Japfa Comfeed Indonesia, Tsuruha Holdings, IAMGOLD , MongoDB , T’Way Holdings, Malaysia Airports Holdings, Samsung Electronics, Sichuan Biokin Pharmaceutical Co Ltd and more

By | Daily Briefs, Most Read

In today’s briefing:

  • ZTO Express (2057 HK): On Track for Double (Maybe Triple) Index Inclusion
  • Solactive Global Uranium & Nuclear Components Index Rebalance Preview: Potential Changes Next Week
  • IDX30/​​LQ45/IDX80 Index Rebalance: Big Impact in Some Stocks with 4 Days to Implementation
  • Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table
  • [Quiddity Index Jan25] MV Junior Gold Miners Index Mar 25 Rebal: Multiple Adds, 4.4% 1-Way Turnover
  • Nasdaq100 Dec2025 Forecast (Part 1): MDB & BIIB in Trouble; UAL & ALNY First Replacements
  • StubWorld: T’Way Air (091810 KS) Takes Off As Key Shareholder Seeks Board Spill
  • Malaysia Airports (MAHB MK): Lower Acceptance Condition Assures Completion
  • Converting Samsung Life’s Samsung Electronics Stake to Long-Term Holdings: Clearing up the Confusion
  • Sichuan Biokin (百利天恒) H-Listing: Impressive Clinical Results so Far


ZTO Express (2057 HK): On Track for Double (Maybe Triple) Index Inclusion

By Brian Freitas

  • With improved liquidity, ZTO Express Cayman (2057 HK) could be added to the HSCEI INDEX early March and then to a global index a couple of weeks later.
  • ZTO Express Cayman (2057 HK) is a lower probability inclusion to the Hang Seng Index (HSI INDEX) given the index committee discretion. Inclusion would further increase the impact.
  • The stock has had a big drawdown recently and the potential index inclusion and passive demand provide a low-risk entry point into the stock, especially hedged with its peers.

Solactive Global Uranium & Nuclear Components Index Rebalance Preview: Potential Changes Next Week

By Brian Freitas

  • Based on prices and turnover from 22 January, there could be one deletion from the index in January. Plus there will be capping and float changes.
  • There are four stocks that meet the inclusion criteria, but all are non-pure play companies, and the index is already at the limit of 15 non-pure play companies.
  • Estimated one-way turnover is 6.8% resulting in a round-trip trade of US$506m. There are many stocks with multiple days of ADV to trade.

IDX30/​​LQ45/IDX80 Index Rebalance: Big Impact in Some Stocks with 4 Days to Implementation

By Brian Freitas


Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table

By Travis Lundy

  • In late December, a Jiji article said Tsuruha & Welcia would look to integrate by end-2025, now that they no longer need SEC approval. Odd language, but we’ll take it.
  • That means we look to what might happen between here and there. The companies will hire Legal and Financial Advisors, wait until both report FY, then start negotiating.
  • What has been the long-term trend and the trend of the last two years is different. It’s worthwhile looking at valuations and expectations to decide how to trade. It’s good.

[Quiddity Index Jan25] MV Junior Gold Miners Index Mar 25 Rebal: Multiple Adds, 4.4% 1-Way Turnover

By Travis Lundy

  • The MV Junior Gold Miners Index represents the performance of small-cap gold and silver mining companies listed around the world.
  • This index is reviewed semi-annually in March and September. During these reviews, names can be added or deleted from the index.
  • Below we take a look at the latest lists of potential ADDs and DELs for the Index Rebal Event in March 2025. 

Nasdaq100 Dec2025 Forecast (Part 1): MDB & BIIB in Trouble; UAL & ALNY First Replacements

By Dimitris Ioannidis


StubWorld: T’Way Air (091810 KS) Takes Off As Key Shareholder Seeks Board Spill

By David Blennerhassett

  • A double dose of stubs this week! T’Way Air (091810 KS)‘s second-largest shareholder is seeking to spill the board. T’way Air and T’Way Holdings (004870 KS) are up big time.
  • Preceding my comments on the T’way Group are the current setup/unwind tables for Asia-Pacific Holdcos.
  • These relationships trade with a minimum liquidity of US$1mn, and a % market capitalisation >20%.

Malaysia Airports (MAHB MK): Lower Acceptance Condition Assures Completion

By David Blennerhassett

  • On the 17th January, Malaysia Airports Holdings (MAHB MK)‘s Offer was extended to the 24th January. Shares held by the Consortium plus tendering was then 86.18%. This looked done.
  • The closing date of the Offer could have been pushed out to 4th Feb. However the consortium has now opted to lower the acceptance threshold to 85% from 90%. 
  • Because of the revision, shareholders can withdraw shares tendered before the 28th January. But why would they? This is now very much done. And trading accordingly. 

Converting Samsung Life’s Samsung Electronics Stake to Long-Term Holdings: Clearing up the Confusion

By Sanghyun Park

  • Samsung Life needs FSC approval for a 10-year holding plan on its Samsung Electronics stake. Without it, the whole plan could fall apart, so it’s all about regulatory green lights.
  • If FSC approves Samsung Life’s long-term holding, they can’t sell those shares for at least 5 years—no exit strategy for the next half-decade due to regulatory rules.
  • Samsung Life will convert part of its stake into long-term holdings, signaling how future buybacks and special dividends will balance in Samsung Electronics’ next shareholder return program.

Sichuan Biokin (百利天恒) H-Listing: Impressive Clinical Results so Far

By Ke Yan, CFA, FRM

  • Sichuan Biokin is looking at a A-H listing and is looking to raise up to USD 500 million. 
  • In this note we look at the company’s fundamentals briefly including its heavyweight product BL-B01D1. We also examine its deal with BMS.
  • The stock has performed well on Shanghai STAR board since its A share listing. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief TMT/Internet: Samsung Electronics, OpenAI, AU Optronics, Bharti Airtel, Blend Labs and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • Converting Samsung Life’s Samsung Electronics Stake to Long-Term Holdings: Clearing up the Confusion
  • Stargate. It’s Not All About You Microsoft. Or You Either Elon
  • Tech Supply Chain Tracker (25-Jan-2025): HTC and VIA’s future?
  • Lucror Analytics – Morning Views Asia
  • Blend Labs Inc (BLND) – Friday, Oct 25, 2024


Converting Samsung Life’s Samsung Electronics Stake to Long-Term Holdings: Clearing up the Confusion

By Sanghyun Park

  • Samsung Life needs FSC approval for a 10-year holding plan on its Samsung Electronics stake. Without it, the whole plan could fall apart, so it’s all about regulatory green lights.
  • If FSC approves Samsung Life’s long-term holding, they can’t sell those shares for at least 5 years—no exit strategy for the next half-decade due to regulatory rules.
  • Samsung Life will convert part of its stake into long-term holdings, signaling how future buybacks and special dividends will balance in Samsung Electronics’ next shareholder return program.

Stargate. It’s Not All About You Microsoft. Or You Either Elon

By William Keating

  • President Donald Trump announced the Stargate Project, a new company which intends to invest $500 billion over four years building new AI infrastructure for OpenAI in the United States.
  • Elon Musk is miffed, Microsoft says they “approved” the project and have a new Right of First Refusal agreement in place with OpenAI. 
  • Stargate is exclusively for OpenAI and the press release states that its mission is to provide a strategic capability to protect the national security of America and its allies.

Tech Supply Chain Tracker (25-Jan-2025): HTC and VIA’s future?

By Tech Supply Chain Tracker

  • HTC and VIA are focusing on niche markets and expanding technological capabilities to stay relevant, while Japanese toolmakers turn to AI amid China market uncertainty.
  • Nvidia CEO highlights strategic partnership with China’s robotics unicorns, as Acer expands into lifestyle products with Acerpure line.
  • Singapore and Malaysia remain optimistic despite US AI chip restrictions, while India’s local EMS and semiconductor industries show growth in the technology sector.

Lucror Analytics – Morning Views Asia

By Trung Nguyen

  • In today’s Morning Views publication we comment on developments of the following high yield issuers: Bharti Airtel, SK Hynix, Adani Green Energy, Wynn Macau, New World Development
  • In the US, initial jobless claims for the week ended January 18th rose slightly to 223 k (220 k e / 217 k p). Meanwhile, continuing claims climbed to a three-year high of 1.90 mn (1.87 mn e / 1.85 mn p).
  • Treasuries ended mixed yesterday. The yield on the 2Y UST declined 1 bp to 4.29%, while the yield on the 10Y UST grew 3 bps to 4.64%.

Blend Labs Inc (BLND) – Friday, Oct 25, 2024

By Value Investors Club

  • BLND’s stock price has decreased, resembling CVNA’s past struggles
  • BLND has been restructuring its cost base and balance sheet to prepare for future growth
  • The company, led by a young CEO, is poised for potential recovery and positive earnings revisions, drawing parallels to CVNA’s path to success

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Dr. Reddy’s Laboratories, Beta Bionic, Akebia Therapeutics, Astellas Pharma and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Dr. Reddy’s Laboratories (DRRD IN): Q3FY25 Result- Subdued US Business Dents Margin; Somber Outlook
  • Beta Bionic, Inc. (BBNX): IPO Is An “Execution Story” And in Growth Mode
  • Akebia Therapeutics Inc (AKBA) – Friday, Oct 25, 2024
  • Astellas Pharma (4503 JP): Xtandi & Forex Lead To Guidance Revision, Impairment Losses One Off Burnt


Dr. Reddy’s Laboratories (DRRD IN): Q3FY25 Result- Subdued US Business Dents Margin; Somber Outlook

By Tina Banerjee

  • Dr. Reddy’s Laboratories (DRRD IN) reported Q3FY25 US business revenue of INR33.8B, up 1% YoY, mainly dragged by lower contribution from Lenalidomide. Q3FY25 EBITDA margin deteriorated to 27.5% (Q3FY24: 29.3%).
  • Limited growth catalysts remain major overhang. No near-term key launches lined-up to fill the void created by Lenalidomide. Moreover, paltry new launches in the U.S. entail limited revenue visibility.
  • Lack of near-term catalyst and bleak growth outlook justify cheaper valuation of Dr. Reddy’s. We do not consider Dr. Reddy’s as value buying opportunity and remain bearish on the name.

Beta Bionic, Inc. (BBNX): IPO Is An “Execution Story” And in Growth Mode

By IPO Boutique

  • The company has jumped from just eight sales territories in Q2 2023 to 43 sales to end 2024 with more than 15,000 units installed.
  • An existing shareholder is on the cover of the prospectus with a concurrent private placement
  • Medical Device IPOs have a strong history of success as many are poised for growth

Akebia Therapeutics Inc (AKBA) – Friday, Oct 25, 2024

By Value Investors Club

  • Akebia Therapeutics aims to challenge the standard of care for anemia management in chronic kidney disease in the USA
  • Despite setbacks with FDA rejection of new drug Vafseo, company holds growth potential
  • Aims to have over 75,000 patients prescribed to Vafseo by end of 2026, leading to significant sales growth and operating profit; stock seen as undervalued with potential to reach price target of $5.00+

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


Astellas Pharma (4503 JP): Xtandi & Forex Lead To Guidance Revision, Impairment Losses One Off Burnt

By Tina Banerjee

  • Astellas Pharma (4503 JP) revised FY25 revenue guidance upward to ¥1900B on robust Xtandi performance and favourable forex movement. Core profits and margins will also see upward revisions and expansions.
  • The company will record an impairment charge of ¥176B for intangible assets this fiscal. As a result, FY25 operating profit on reported basis will come down to ¥11B from ¥80B.
  • Recently, Astellas has received approval for Vyloy and label expansion approval for Padcev in China. Label expansion application for Izervay in the U.S. has been accepted by the FDA.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars